Contract Manufacturing

Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) announced that they reached an agreement with the UK government to supply up to 60 million doses of a COVID-19 vaccine. Subject to a final contract, the UK government will receive the doses of a vaccine candidate developed by the two companies in partnership and based on the recombinant protein-based technology Sanofi used to…

Fujifilm Diosynth Biotechnologies announced that its College Station, Texas, site will manufacture a COVID-19 vaccine candidate under a $265 million federal contract. The contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies said it received the federal task order through the Texas A&M System Center for Innovation in Advanced Development &…

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver its INO-4800 COVID-19 vaccine candidate directly into the skin.…

Smiths Medical announced today that it has landed a federal contract to produce more than 78 million syringe-and-needle units and $20 million in federal funding to expand its Keene, N.H. plant to produce them. The Plymouth, Minn.-based company said it received an order for 78.6 million syringe-and-needle units and that BARDA and the Joint Program Executive…

Moderna (NSDQ:MRNA) announced today that Laboratorios Farmacéuticos Rovi has agreed to make Moderna’s COVID-19 vaccine candidate in its Madrid, Spain facility. The contract for large-scale, commercial fill-finish manufacturing in Spain is but the latest that Moderna has secured as it moves forward with Phase 3 of the clinical trial for its COVID-19 vaccine candidate. Moderna in…

Emergent BioSolutions announced a five-year manufacturing agreement with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals for the parent company’s SARS-CoV-2 vaccine candidate. Gaithersburg, Md.-based Emergent is set to provide contract development and manufacturing services to produce Johnson & Johnson’s Ad26.COV2-S vaccine candidate at scale over five years, with the deal valued at approximately $480 million for…

The U.S. Health and Human Services Dept. and Defense Dept. announced a joint agreement with Novavax  (NSDQ:NVAX) worth $1.6 billion to scale the manufacturing of its COVID-19 vaccine candidate. Gaithersburg, Md.-based Novavax’s commercial-scale manufacturing is expected to produce 100 million doses of the investigational vaccine that would become available for use in clinical trials or,…

Moderna (NSDQ:MRNA) and Catalent (NYSE:CTLT) today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Ind. Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support production of an initial 100 million…

The U.S. Dept. of Health & Human Services (HHS) and Dept. of Defense (DoD) announced a joint effort to increase manufacturing for vials earmarked for COVID-19-related drugs and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), as part of HHS, collaborated with DoD to provide funding for U.S.-based companies Corning Inc. and SiO2 Materials…

Sherlock Biosciences announced today that it will collaborate with Integrated DNA Technologies (IDT) to enable large-scale manufacturing of the Sherlock CRISPR SARS-CoV-2 kit for COVID-19 detection. Officials at Cambridge, Mass.–based Sherlock Biosciences think the company’s CRISPR-based diagnostic test, which recently received an FDA emergency use authorization, will increase testing capacity and decreasing time to result…